Render Target: STATIC
Render Timestamp: 2024-12-26T10:49:52.998Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-04-24 09:10:52.436
Product last modified at: 2024-05-30T07:12:34.402Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

Histone H3 Lysine Mutant-Specific Antibody Sampler Kit #25520

    Product Information

    Product Description

    The Histone H3 Lysine Mutant-Specific Antibody Sampler Kit provides an economical means of detecting Lys (K) to Meth (M) cancer driver mutations in histone H3. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Specificity / Sensitivity

    Histone H3 (K9M Mutant Specific) (E2E9L) Rabbit mAb recognizes endogenous levels of K9M mutant histone H3.1, H3.2, and H3.3 proteins. This antibody does not cross-react with wild-type histone H3.1, H3.2, or H3.3 proteins. Histone H3 (K27M Mutant Specific) (D3B5T) Rabbit mAb recognizes endogenous levels of K27M mutant histone H3.1, H3.2, and H3.3 proteins. This antibody may cross-react with wild-type histone H3.1, H3.2, and H3.3 when used at a high concentration. Careful titration of this antibody may be required to obtain optimal specificity. Histone H3 (K36M Mutant Specific) Antibody recognizes endogenous levels of K36M mutant histone H3.1, H3.2, and H3.3 proteins. This antibody may show slight cross-reactivity with wild-type histone H3.1, H3.2, or H3.3 when used at a high concentration. Careful titration of this antibody may be required to obtain optimal specificity. Histone H3 (D1H2) XP® Rabbit mAb detects endogenous levels of total Histone H3 protein, including isoforms H3.1, H3.2, and H3.3. This antibody also detects the Histone H3 variant CENP-A. This antibody does not cross-react with other core histones.

    Source / Purification

    Mutant-specific histone H3 monoclonal antibodies were produced by immunizing animals with synthetic peptides corresponding to K9M, K27M, or K36M mutant sequences of human histone H3.3 protein. Total histone H3 monoclonal antibody was produced by immunizing animals with a synthetic peptide corresponding to the carboxy terminus of human histone H3 protein.

    Background

    Multiple exome sequencing analyses have uncovered a high frequency of histone H3 driver mutations in a number of different cancers, including diffuse intrinsic pontine glioma (DIPG), chondroblastoma, sarcomas, and HPV-negative head and neck squamous cell carcinoma. Previous studies have shown that lysine to methionine histone mutations in these cancers act as potent inhibitors of their respective lysine methyltransferases, resulting in gross alterations to the histone methylation landscape and deregulation of gene expression. In DIPG for example, the histone H3 K27M mutation is accompanied by a dramatic reduction in the levels of polycomb repressive complex 2 (PRC2)-mediated tri-methylation of histone H3 lysine 27, changes in the distribution of PRC2 on the genome, and altered expression of genes associated with various cancer pathways (1-3). In chondrocytomas, the histone H3 K36M mutation functions to inhibit the WHSC1 (MMSET) and SETD2 histone methyltransferases, resulting in a reduction in the levels of histone H3 lysine 36 tri-methylation and deregulation of a number of cancer-associated genes (4). Similar to the H3K27M and H3K36M mutations, the histone H3 K9M mutation has been shown to inhibit the H3K9-directed histone methyltransferase G9a, resulting in reduced levels of histone H3 lysine 9 trimethylation (5). Given the widespread role of G9a in the regulation of gene expression, it is likely that this K9M mutation also plays a role in cancer.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.